ZA972601B - Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer - Google Patents
Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancerInfo
- Publication number
- ZA972601B ZA972601B ZA972601A ZA972601A ZA972601B ZA 972601 B ZA972601 B ZA 972601B ZA 972601 A ZA972601 A ZA 972601A ZA 972601 A ZA972601 A ZA 972601A ZA 972601 B ZA972601 B ZA 972601B
- Authority
- ZA
- South Africa
- Prior art keywords
- cancer
- alpha1
- prevention
- treatment
- adrenoreceptor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method for treating or preventing a cancer in a mammal which comprises administering to said mammal an amount of a drug, comprising an alpha 1-adrenoreceptor antagonist or pharmaceutically acceptable acid addition salt thereof, effective for treating or preventing the cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1422896P | 1996-03-27 | 1996-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA972601B true ZA972601B (en) | 1998-09-28 |
Family
ID=21764236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA972601A ZA972601B (en) | 1996-03-27 | 1997-03-26 | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer |
Country Status (16)
Country | Link |
---|---|
US (1) | US5935962A (en) |
EP (1) | EP0799618B1 (en) |
JP (1) | JPH10101579A (en) |
KR (1) | KR970064607A (en) |
AT (1) | ATE294582T1 (en) |
AU (1) | AU733146B2 (en) |
CA (1) | CA2201089A1 (en) |
DE (1) | DE69733169T2 (en) |
DK (1) | DK0799618T3 (en) |
ES (1) | ES2242207T3 (en) |
HU (1) | HUP9700661A3 (en) |
IL (2) | IL120303A0 (en) |
MY (1) | MY126321A (en) |
NZ (1) | NZ314488A (en) |
TW (1) | TW504386B (en) |
ZA (1) | ZA972601B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1408154A (en) * | 1999-01-27 | 2003-04-02 | 法国电信公司 | Method, system, device for verifying the authenticity of an entity and/or the integrity and/or authenticity of a message |
WO2002015895A2 (en) * | 2000-08-24 | 2002-02-28 | The Regents Of The University Of California | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
DK1293198T3 (en) * | 2001-09-14 | 2005-06-06 | Sanol Arznei Schwarz Gmbh | Transdermal administration device for the treatment of urinary tract disorders |
WO2006052409A2 (en) * | 2004-10-23 | 2006-05-18 | Case Western Reserve University | Peptide and small molecule agonists of epha and their uses |
WO2007109142A2 (en) * | 2006-03-17 | 2007-09-27 | Oregon Health & Science University | M3 muscarinic receptor antagonists for treating tumors |
WO2009131196A1 (en) * | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | Substituted pyrrolidine derivative and use thereof |
EP2595616B1 (en) * | 2010-06-30 | 2016-04-13 | Galderma Research & Development | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
WO2012001065A2 (en) | 2010-06-30 | 2012-01-05 | Galderma Research & Development | Method for preventing or treating skin tumor |
US20120178757A1 (en) * | 2010-12-09 | 2012-07-12 | Nottingham University Hospitals Nhs Trust | Method For The Prevention Of Cancer Metastasis |
GR20200100456A (en) * | 2020-08-03 | 2022-03-09 | Inderes Ltd, | Drug combination and its use in the treatment of cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
US4758569A (en) * | 1987-08-26 | 1988-07-19 | Pfizer Inc. | Doxazosin as an anti-atherosclerosis agent |
DK0564093T3 (en) * | 1992-04-01 | 2000-03-27 | Pfizer | Hydroxylated metabolites and derivatives of doxazosin as antiatherosclerosis agents |
FR2694495B1 (en) * | 1992-08-05 | 1994-09-23 | Synthelabo | Transdermal pharmaceutical preparation containing alfuzosin. |
US5578611A (en) * | 1992-11-13 | 1996-11-26 | Synaptic Pharmaceutical Corporation | Use of α-1C specific compounds to treat benign prostatic hyperplasia |
US5503843A (en) * | 1994-04-22 | 1996-04-02 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
-
1997
- 1997-02-24 IL IL12030397A patent/IL120303A0/en unknown
- 1997-03-20 IL IL12049597A patent/IL120495A/en not_active IP Right Cessation
- 1997-03-24 DK DK97301984T patent/DK0799618T3/en active
- 1997-03-24 DE DE69733169T patent/DE69733169T2/en not_active Expired - Fee Related
- 1997-03-24 AT AT97301984T patent/ATE294582T1/en not_active IP Right Cessation
- 1997-03-24 ES ES97301984T patent/ES2242207T3/en not_active Expired - Lifetime
- 1997-03-24 EP EP97301984A patent/EP0799618B1/en not_active Expired - Lifetime
- 1997-03-26 CA CA002201089A patent/CA2201089A1/en not_active Abandoned
- 1997-03-26 HU HU9700661A patent/HUP9700661A3/en unknown
- 1997-03-26 KR KR1019970010501A patent/KR970064607A/en not_active Application Discontinuation
- 1997-03-26 ZA ZA972601A patent/ZA972601B/en unknown
- 1997-03-26 AU AU16569/97A patent/AU733146B2/en not_active Ceased
- 1997-03-26 MY MYPI97001296A patent/MY126321A/en unknown
- 1997-03-26 NZ NZ314488A patent/NZ314488A/en unknown
- 1997-03-27 US US08/827,137 patent/US5935962A/en not_active Expired - Fee Related
- 1997-03-27 JP JP9075809A patent/JPH10101579A/en active Pending
- 1997-07-12 TW TW086110044A patent/TW504386B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HUP9700661A2 (en) | 1998-11-30 |
TW504386B (en) | 2002-10-01 |
DK0799618T3 (en) | 2005-05-30 |
JPH10101579A (en) | 1998-04-21 |
ATE294582T1 (en) | 2005-05-15 |
US5935962A (en) | 1999-08-10 |
NZ314488A (en) | 2000-09-29 |
HUP9700661A3 (en) | 1999-06-28 |
CA2201089A1 (en) | 1997-09-27 |
AU733146B2 (en) | 2001-05-10 |
MY126321A (en) | 2006-09-29 |
EP0799618B1 (en) | 2005-05-04 |
KR970064607A (en) | 1997-10-13 |
EP0799618A3 (en) | 1997-11-12 |
IL120303A0 (en) | 1997-06-10 |
AU1656997A (en) | 1997-10-02 |
IL120495A0 (en) | 1997-07-13 |
ES2242207T3 (en) | 2005-11-01 |
DE69733169D1 (en) | 2005-06-09 |
EP0799618A2 (en) | 1997-10-08 |
IL120495A (en) | 2004-09-27 |
HU9700661D0 (en) | 1997-05-28 |
DE69733169T2 (en) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
UA41355C2 (en) | Agent for treating neuro-aids | |
MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
NO994165L (en) | Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness | |
MY118986A (en) | Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
IL120495A0 (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
CA2156481A1 (en) | 5-ht2 receptor antagonist compositions useful in treating venous conditions | |
GR3021813T3 (en) | Method of treating alopecia | |
CA2289017A1 (en) | The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer | |
CZ223199A3 (en) | Use of comt inhibitors or pharmaceutically acceptable salts or esters thereof for preparing a medicament for prevention diabetic vascular dysfunctions | |
IL126158A0 (en) | Method for treating substance abuse | |
WO1995005364A3 (en) | Inhibitors of biogenic amine transporters | |
DE69800906D1 (en) | Use of olanzapine in the manufacture of a medicament for the treatment of cerebral focal ischemia | |
DK1019066T3 (en) | Methods and Preparations for the Prevention and Treatment of Heartburn | |
EP0384302A3 (en) | Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome | |
EE04951B1 (en) | Use of R - (+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol for the treatment of sleep disorders | |
WO1998025594A3 (en) | Lamotrigine in the treatment and prophylaxis of migraine | |
BR9713828A (en) | Treatment of highly vascular tumors | |
EA199800820A1 (en) | METHOD OF TREATING ABUSE OF MEDICINES | |
ZA977873B (en) | Dosage form and method for administering drug. | |
EP1095655A3 (en) | NK-1 receptor antagonists and eletriptan for the treatment of migraine | |
EP1712231A3 (en) | Method for improving the pharmacokinetics of tipranavir |